Exploiting the anti-HIV 6-desfluoroquinolones to design multiple ligands

It is getting clearer that many drugs effective in different therapeutic areas act on multiple rather than single targets. The application of polypharmacology concepts might have numerous advantages especially for disease such as HIV/AIDS, where the rapid emergence of resistance requires a complex c...

Full description

Bibliographic Details
Published in:Bioorganic & Medicinal Chemistry
Main Authors: Sancineto L., Iraci N., Barreca M. L., Massari S., Manfroni G., Corazza G., Cecchetti V., Marcello A., Daelemans D., Pannecouque C., Tabarrini O.
Other Authors: Sancineto, L., Iraci, N., Barreca, M. L., Massari, S., Manfroni, G., Corazza, G., Cecchetti, V., Marcello, A., Daelemans, D., Pannecouque, C., Tabarrini, O.
Format: Article in Journal/Newspaper
Language:English
Published: Elsevier Ltd 2014
Subjects:
DML
RT
Online Access:http://hdl.handle.net/11570/3189073
https://doi.org/10.1016/j.bmc.2014.07.018
id ftunimessinairis:oai:iris.unime.it:11570/3189073
record_format openpolar
spelling ftunimessinairis:oai:iris.unime.it:11570/3189073 2024-04-21T08:01:03+00:00 Exploiting the anti-HIV 6-desfluoroquinolones to design multiple ligands Sancineto L. Iraci N. Barreca M. L. Massari S. Manfroni G. Corazza G. Cecchetti V. Marcello A. Daelemans D. Pannecouque C. Tabarrini O. Sancineto, L. Iraci, N. Barreca, M. L. Massari, S. Manfroni, G. Corazza, G. Cecchetti, V. Marcello, A. Daelemans, D. Pannecouque, C. Tabarrini, O. 2014 http://hdl.handle.net/11570/3189073 https://doi.org/10.1016/j.bmc.2014.07.018 eng eng Elsevier Ltd info:eu-repo/semantics/altIdentifier/wos/WOS:000341293300015 volume:22 issue:17 firstpage:4658 lastpage:4666 numberofpages:9 journal:BIOORGANIC & MEDICINAL CHEMISTRY http://hdl.handle.net/11570/3189073 doi:10.1016/j.bmc.2014.07.018 info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84906934907 6-Desfluoroquinolone Anti-HIV compound DML RT Transactivation info:eu-repo/semantics/article 2014 ftunimessinairis https://doi.org/10.1016/j.bmc.2014.07.018 2024-03-25T18:07:14Z It is getting clearer that many drugs effective in different therapeutic areas act on multiple rather than single targets. The application of polypharmacology concepts might have numerous advantages especially for disease such as HIV/AIDS, where the rapid emergence of resistance requires a complex combination of more than one drug. In this paper, we have designed three hybrid molecules combining WM5, a quinolone derivative we previously identified as HIV Tat-mediated transcription (TMT) inhibitor, with the tricyclic core of nevirapine and BILR 355BS (BILR) non-nucleoside reverse transcriptase inhibitors (NNRTIs) to investigate whether it could be possible to obtain molecules acting on both transcription steps of the HIV replicative cycle. One among the three designed multiple ligands, reached this goal. Indeed, compound 1 inhibited both TMT and reverse transcriptase (RT) activity. Unexpectedly, while the anti-TMT activity exerted by compound 1 resulted into a selective inhibition of HIV-1 reactivation from latently infected OM10.1 cells, the anti-RT properties shown by all of the synthesized compounds did not translate into an anti-HIV activity in acutely infected cells. Thus, we have herein produced the proof of concept that the design of dual TMT-RT inhibitors is indeed possible, but optimization efforts are needed to obtain more potent derivatives. © 2014 Elsevier Ltd. All rights reserved. Article in Journal/Newspaper DML Università degli Studi di Messina: IRIS Bioorganic & Medicinal Chemistry 22 17 4658 4666
institution Open Polar
collection Università degli Studi di Messina: IRIS
op_collection_id ftunimessinairis
language English
topic 6-Desfluoroquinolone
Anti-HIV compound
DML
RT
Transactivation
spellingShingle 6-Desfluoroquinolone
Anti-HIV compound
DML
RT
Transactivation
Sancineto L.
Iraci N.
Barreca M. L.
Massari S.
Manfroni G.
Corazza G.
Cecchetti V.
Marcello A.
Daelemans D.
Pannecouque C.
Tabarrini O.
Exploiting the anti-HIV 6-desfluoroquinolones to design multiple ligands
topic_facet 6-Desfluoroquinolone
Anti-HIV compound
DML
RT
Transactivation
description It is getting clearer that many drugs effective in different therapeutic areas act on multiple rather than single targets. The application of polypharmacology concepts might have numerous advantages especially for disease such as HIV/AIDS, where the rapid emergence of resistance requires a complex combination of more than one drug. In this paper, we have designed three hybrid molecules combining WM5, a quinolone derivative we previously identified as HIV Tat-mediated transcription (TMT) inhibitor, with the tricyclic core of nevirapine and BILR 355BS (BILR) non-nucleoside reverse transcriptase inhibitors (NNRTIs) to investigate whether it could be possible to obtain molecules acting on both transcription steps of the HIV replicative cycle. One among the three designed multiple ligands, reached this goal. Indeed, compound 1 inhibited both TMT and reverse transcriptase (RT) activity. Unexpectedly, while the anti-TMT activity exerted by compound 1 resulted into a selective inhibition of HIV-1 reactivation from latently infected OM10.1 cells, the anti-RT properties shown by all of the synthesized compounds did not translate into an anti-HIV activity in acutely infected cells. Thus, we have herein produced the proof of concept that the design of dual TMT-RT inhibitors is indeed possible, but optimization efforts are needed to obtain more potent derivatives. © 2014 Elsevier Ltd. All rights reserved.
author2 Sancineto, L.
Iraci, N.
Barreca, M. L.
Massari, S.
Manfroni, G.
Corazza, G.
Cecchetti, V.
Marcello, A.
Daelemans, D.
Pannecouque, C.
Tabarrini, O.
format Article in Journal/Newspaper
author Sancineto L.
Iraci N.
Barreca M. L.
Massari S.
Manfroni G.
Corazza G.
Cecchetti V.
Marcello A.
Daelemans D.
Pannecouque C.
Tabarrini O.
author_facet Sancineto L.
Iraci N.
Barreca M. L.
Massari S.
Manfroni G.
Corazza G.
Cecchetti V.
Marcello A.
Daelemans D.
Pannecouque C.
Tabarrini O.
author_sort Sancineto L.
title Exploiting the anti-HIV 6-desfluoroquinolones to design multiple ligands
title_short Exploiting the anti-HIV 6-desfluoroquinolones to design multiple ligands
title_full Exploiting the anti-HIV 6-desfluoroquinolones to design multiple ligands
title_fullStr Exploiting the anti-HIV 6-desfluoroquinolones to design multiple ligands
title_full_unstemmed Exploiting the anti-HIV 6-desfluoroquinolones to design multiple ligands
title_sort exploiting the anti-hiv 6-desfluoroquinolones to design multiple ligands
publisher Elsevier Ltd
publishDate 2014
url http://hdl.handle.net/11570/3189073
https://doi.org/10.1016/j.bmc.2014.07.018
genre DML
genre_facet DML
op_relation info:eu-repo/semantics/altIdentifier/wos/WOS:000341293300015
volume:22
issue:17
firstpage:4658
lastpage:4666
numberofpages:9
journal:BIOORGANIC & MEDICINAL CHEMISTRY
http://hdl.handle.net/11570/3189073
doi:10.1016/j.bmc.2014.07.018
info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84906934907
op_doi https://doi.org/10.1016/j.bmc.2014.07.018
container_title Bioorganic & Medicinal Chemistry
container_volume 22
container_issue 17
container_start_page 4658
op_container_end_page 4666
_version_ 1796941402509148160